{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:31:37Z","timestamp":1761921097484,"version":"3.37.3"},"reference-count":31,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Pulmonology"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with cystic fibrosis (CF)\u00a0may be treated with piperacillin\u2010tazobactam (PZT)\u00a0for acute pulmonary exacerbations. Extending the infusion of PZT is one strategy to increase efficacy. Direct comparison, with respect to the incidence of acute kidney injury (AKI),\u00a0between these two strategies has not been evaluated in pediatric patients with CF. The primary objective of this study was to compare the incidence of AKI in pediatric CF patients receiving extended infusion (EI) PZT versus traditional infusion (TI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This IRB\u2010approved, retrospective analysis included patients ages 30 days to 18 years that received PZT for at least 48\u2009h between January 1, 2008, and January 1, 2020. PZT was infused over 30\u2009min\u00a0(TI group) or 4\u2009h\u00a0(EI group).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Two hundred and four patients were included (TI: 109, EI: 95). Median age was 8 years (4\u201313) and 7 years (3\u201312) in the TI and EI groups (<jats:italic>p<\/jats:italic>\u2009=\u20090.15). The groups did not differ significantly in their baseline characteristics. There were 12 (11%) AKIs in the TI group and 8 (8.4%) in the EI group (<jats:italic>p<\/jats:italic>\u2009=\u20090.53). There was one occurrence of serum sickness in the TI group and none in the EI group. The incidence of thrombocytopenia was similar between the two groups. Median treatment duration was 8 days (5\u201311) and 9 days (5\u201313) for the TI and EI groups, respectively (<jats:italic>p<\/jats:italic>\u2009=\u20090.24).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>There was no significant increase in AKI in pediatric patients with CF receiving PZT by EI compared with\u00a0TI. EI may be utilized to optimize the pharmacokinetics of PZT in pediatric CF patients.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ppul.26299","type":"journal-article","created":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T04:59:50Z","timestamp":1672721990000},"page":"1092-1099","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of the safety of piperacillin\u2010tazobactam extended infusion in pediatric cystic fibrosis patients"],"prefix":"10.1002","volume":"58","author":[{"given":"Daniel","family":"Riggsbee","sequence":"first","affiliation":[{"name":"Riley Hospital for Children at IU Health  Indianapolis Indiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Engdahl","sequence":"additional","affiliation":[{"name":"Riley Hospital for Children at IU Health  Indianapolis Indiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6049-0481","authenticated-orcid":false,"given":"Rebecca S.","family":"Pettit","sequence":"additional","affiliation":[{"name":"Riley Hospital for Children at IU Health  Indianapolis Indiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.14.1529"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.JAA.0000515540.36581.92"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200812-1845PP"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200909-1421OC"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00019-18"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2016.01.008"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2018.11.013"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.22669"},{"key":"e_1_2_9_10_1","unstructured":"Pfizer Inc. Piperacillin\u2010tazobactam [package insert]. Wyeth Pharmaceuticals Inc: Pfizer Inc.\u00a02017."},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piy030"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23718"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-020-01071-8"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-22.3.212"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9060329"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00174-09"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.2146\/sp150007"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01477-06"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/0300060519855575"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2013.03.005"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002231"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.05.005"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001445"},{"issue":"4","key":"e_1_2_9_24_1","first-page":"283","article-title":"Piperacillin\/tazobactam in continuous infusion versus intermittent infusion in children with febrile neutropenia","volume":"71","author":"Sol\u00f3rzano\u2010Santos F","year":"2019","journal-title":"Rev Invest Clin"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01260-19"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020975646"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.25817"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00871-17"},{"issue":"2","key":"e_1_2_9_29_1","first-page":"187","article-title":"Extended infusion of beta\u2010lactams is associated with improved outcomes in pediatric patients","volume":"26","author":"Zembles TN","year":"2021","journal-title":"J Pediatr Pharmacol Ther"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp100694"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2016.04.005"},{"issue":"7","key":"e_1_2_9_32_1","article-title":"A review of Trikafta: triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy","volume":"13","author":"Zaher A","year":"2021","journal-title":"Cureus"}],"container-title":["Pediatric Pulmonology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ppul.26299","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ppul.26299","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ppul.26299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T20:44:04Z","timestamp":1692305044000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ppul.26299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1002\/ppul.26299"],"URL":"https:\/\/doi.org\/10.1002\/ppul.26299","archive":["Portico"],"relation":{},"ISSN":["8755-6863","1099-0496"],"issn-type":[{"type":"print","value":"8755-6863"},{"type":"electronic","value":"1099-0496"}],"subject":[],"published":{"date-parts":[[2023,1,13]]},"assertion":[{"value":"2022-07-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}